

WEST**End of Result Set**

Generate Collection

Print

L7: Entry 1 of 1

File: JPAB

Apr 16, 1991

PUB-NO: JP403090035A
DOCUMENT-IDENTIFIER: JP 03090035 A
TITLE: NONPARENTERAL MEDICINAL COMPOSITION FOR INSULIN

PUBN-DATE: April 16, 1991

INVENTOR-INFORMATION:

NAME

COUNTRY

CAMPFIELD, LEROY ARTHUR

DAVIDOVICH, ALBERTO

INFELD, MARTIN HOWARD

SHAH, NAVNIT

SMITH, FRANCOISE JEANNE

UNOWSKY, JOEL

ASSIGNEE-INFORMATION:

NAME

COUNTRY

F HOFFMANN LA ROCHE AG

APPL-NO: JP02218853

APPL-DATE: August 20, 1990

INT-CL (IPC): A61K 37/26; A61K 47/12; A61K 47/44

ABSTRACT:

PURPOSE: To obtain a medicinal composition formulated with an alkali metal cocoate as absorption promoter, thus markedly promoted in the absorption of nonparenterally administered insulin into blood flow and such insulin's bioavailability.

CONSTITUTION: This composition comprises (A) an enough amount of insulin to reduce blood sugar, (B) an enough amount of an alkali metal cocoate to promote insulin absorption in vivo (as the alkali metal, Na or K is preferable), and (C) at one's discretion, a pharmaceutically permissible support in the weight ratio B/A of (500:1) to (1:1), pref. (50:1) to (5:1). The mode of administration of this composition is e.g. oral perrectum, intraoral cavity, sublingual, nasal one, being esp. pref. administration mode via buccal film.

COPYRIGHT: (C)1991,JPO

WEST**End of Result Set**

Generate Collection

Print

L9: Entry 6 of 6

File: DWPI

Jan 24, 1990

DERWENT-ACC-NO: 1990-024068

DERWENT-WEEK: 199004

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Compsn. to enhance absorption and bio-availability of insulin - comprises insulin and polyoxyethylene glycol (6-18C) carboxylic acid glyceride ester

INVENTOR: CAMPFIELD, L A; DAVIDOVICH, A W ; INFELD, M H ; SHAH, N ; SMITH, F J ; UNOWSKY, J ; DAVIDOVICH, A

PATENT-ASSIGNEE:

ASSIGNEE

CODE

HOFFMANN LA ROCHE & CO AG F

HOFF

HOFFMANN-LA ROCHE AG

HOFF

PRIORITY-DATA: 1988US-0222682 (July 21, 1988)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 351651 A	January 24, 1990	E	019	
DE 68909135 E	October 21, 1993		000	A61K037/26
EP 351651 B1	September 15, 1993	E	022	A61K037/26
ES 2045276 T3	January 16, 1994		000	A61K037/26
JP 02073021 A	March 13, 1990		000	

DESIGNATED-STATES: AT BE CH DE ES FR GB IT LI LU NL SE AT BE CH DE ES FR GB IT LI LU NL SE

CITED-DOCUMENTS: 1.Jnl.Ref; A3...199041 ; EP 225189 ; FR 2313914 ; No-SR.Pub ; 2.Jnl.Ref ; GB 1554157

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 351651A	July 6, 1989	1989EP-0112310	
DE 68909135E	July 6, 1989	1989DE-0609135	
DE 68909135E	July 6, 1989	1989EP-0112310	
DE 68909135E		EP 351651	Based on
EP 351651B1	July 6, 1989	1989EP-0112310	
ES 2045276T3	July 6, 1989	1989EP-0112310	
ES 2045276T3		EP 351651	Based on
JP 02073021A	July 19, 1989	1989JP-0184851	

INT-CL (IPC): A61K 37/26; A61K 47/14

ABSTRACTED-PUB-NO: EP 351651A

BASIC-ABSTRACT:

A non-parenteral compsn. comprises (a) a blood sugar-lowering amt. of insulin, (b) an amt. of a polyoxyethyleneglycol 6-18C carboxylic acid glyceride ester sufficient to enhance the absorption of the insulin into the body, and (c) opt. a carrier.

Pref. (b) is suitably derived from a 6-18C fatty acid or fatty acid combination, pref. a saturated acid, esp. capric and/or caprylic acid. The polyoxyethylene glycol from which (b) is erived pref. has m.w. 200-1200, esp. 300-600. The wt. ratio of (b) to (a) is suitably in the range 500:1 to 1:1, pref. 60:1 to 20:1. A dosage form of the compsn. generally contains 20-500 units of insulin (25 units equals about 1 mg.). Pref. the compsn. is for oral or buccal administration. Carriers and additives are conventional. The use of enteric coated capsules is pref.

ADVANTAGE - The (b) ingredient is highly effective in promoting the absorption and bioavailability of insulin via administration routes other than parenteral injection.
ABSTRACTED-PUB-NO:

EP 351651B

EQUIVALENT-ABSTRACTS:

A non-parenteral pharmaceutical composition comprising (a) a blood sugar-lowering amount of insulin, (b) an amount of a polyoxyethylene glycol-C6 to C18 carboxylic acid glyceride ester sufficient to enhance the absorption of the insulin into the body, and (c) optionally, a pharmaceutically acceptable carrier.

CHOSEN-DRAWING: Dwg.0/8 Dwg.0/8

TITLE-TERMS: COMPOSITION ENHANCE ABSORB BIO AVAILABLE INSULIN COMPRISE INSULIN
POLYOXYETHYLENE GLYCOL CARBOXYLIC ACID GLYCERIDE ESTER

DERWENT-CLASS: A96 B04 B07

CPI-CODES: A10-E07C; A12-V01; B04-B02D2; B04-C03C; B12-H05;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

H4 H402 H482 H5 H589 H8 J0 J011 J2 J271
M210 M215 M216 M220 M221 M222 M223 M224 M225 M231
M232 M233 M262 M281 M312 M313 M321 M323 M332 M342
M343 M383 M393 M423 M431 M510 M520 M530 M540 M620
M782 M903 V743
Registry Numbers
1327U 0502U

Chemical Indexing M1 *02*

Fragmentation Code

F012 F014 F423 F521 G010 G013 G100 H1 H100 H101
H181 H182 H4 H401 H441 H481 H8 J0 J011 J012
J1 J111 J171 J172 J3 J371 K0 K2 K224 L2
L250 M280 M311 M312 M313 M314 M315 M320 M321 M322
M331 M332 M333 M340 M342 M343 M349 M371 M381 M391
M392 M423 M431 M510 M520 M521 M530 M531 M540 M620
M782 M903 M904 M910 P816 V0 V621 V901 V902 V917
V922
Specific Compounds
01851M
Registry Numbers
1327U 0502U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 1851U

POLYMER-MULTIPUNCH-CODES-AND-KEY-SERIALS:

Key Serials: 0013 0231 0789 0810 1279 1306 1588 1592 1977 1980 3201 3202 1999 2002 2014 2585
2766

Multipunch Codes: 014 028 034 039 04- 05- 066 067 070 147 198 229 231 239 240 252 27& 31- 336
38- 525 55& 56& 575 583 589 645 688 720

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1990-010562

WEST

Generate Collection

Print

L9: Entry 5 of 6

File: DWPI

Feb 27, 1991

DERWENT-ACC-NO: 1991-059344
DERWENT-WEEK: 199109
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: A non-parenteral pharmaceutical compsn. for insulin - comprises specified amt. of insulin, an amt. of an alkali metal cocoate and opt. a pharmaceutically acceptable carrier

INVENTOR: CAMPFIELD, L A; DAVIDOVICH, A ; INFELD, M H ; SHAH, N ; SMITH, F J ; UNOWSKY, J ; DAVIDOVICH, A W

PATENT-ASSIGNEE:

ASSIGNEE

CODE

HOFFMANN LA ROCHE & CO AG F

HOFF

HOFFMANN-LA ROCHE AG

HOFF

PRIORITY-DATA: 1989US-0396486 (August 21, 1989)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 414080 A	February 27, 1991		000	
DE 69006662 E	March 24, 1994		000	A61K037/26
EP 414080 B1	February 16, 1994	E	027	A61K037/26
ES 2062227 T3	December 16, 1994		000	A61K037/26
JP 03090035 A	April 16, 1991		000	

DESIGNATED-STATES: AT BE CH DE ES FR GB IT LI LU NL SE AT BE CH DE DK ES FR GB IT LI LU NL SE

CITED-DOCUMENTS: 2.Jnl.Ref; A3...199131 ; EP 225189 ; EP 351651 ; NoSR.Pub ; WO 8706137 ; 1.Jnl.Ref

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 414080A	August 11, 1990	1990EP-0115452	
DE 69006662E	August 11, 1990	1990DE-0606662	
DE 69006662E	August 11, 1990	1990EP-0115452	
DE 69006662E		EP 414080	Based on
EP 414080B1	August 11, 1990	1990EP-0115452	
ES 2062227T3	August 11, 1990	1990EP-0115452	
ES 2062227T3		EP 414080	Based on
JP 03090035A	August 20, 1990	1990JP-0218853	

INT-CL (IPC): A61K 9/48; A61K 9/70; A61K 37/26; A61K 47/12

ABSTRACTED-PUB-NO: EP 414080A
BASIC-ABSTRACT:

A non-parenteral pharmaceutical compsn. comprises a) a blood sugar-lowering amt. of insulin, b) an amt. of an alkali metal cocoate sufficient to enhance the absorption of the insulin into the body, and C) opt. a pharmaceutically acceptable carrier. Pref. the cocoate comprises a mixt. of two or more 8-18C fatty acids, or esters, of the acid, with glycerol. The fatty acids comprise caprylic, capric, lauric, myristic, palmitic and stearic acids. The alkali metal of the cocoate is potassium. The wt. of component (b) to component (a) is 60:1 to 20:1.

USE/ADVANTAGE - By co-administering an amt. of alkali metal cocoate, the absorption into the blood stream and bioavailability of the non-parenterally administered insulin is significantly enhanced. The compsn. is useful for treating conditions of hyperglycemia such as diabetes mellitus.

ABSTRACTED-PUB-NO:

EP 414080B

EQUIVALENT-ABSTRACTS:

A non-parenteral pharmaceutical composition comprising (a) a blood sugar-lowering amount of insulin, (b) an amount of an alkali metal cocoate sufficient to enhance the absorption of the insulin into the body, and (c) optionally, a pharmaceutically acceptable carrier.

CHOSEN-DRAWING: Dwg.0/12 Dwg.0/12

TITLE-TERMS: NON PARENTERAL PHARMACEUTICAL COMPOSITION INSULIN COMPRISE SPECIFIED AMOUNT INSULIN AMOUNT ALKALI METAL OPTION PHARMACEUTICAL ACCEPT CARRY

DERWENT-CLASS: B04 B05

CPI-CODES: B04-B02D2; B10-E04C; B12-H05;

CHEMICAL-CODES:

Chemical Indexing M1 *01*

Fragmentation Code

F012 F014 F423 F521 G010 G013 G100 H1 H100 H101
H181 H182 H4 H401 H441 H481 H8 J0 J011 J012
J1 J111 J171 J172 J3 J371 K0 K2 K224 L2
L250 M280 M311 M312 M313 M314 M315 M320 M321 M322
M331 M332 M333 M340 M342 M343 M349 M371 M381 M391
M392 M423 M431 M510 M520 M521 M530 M531 M540 M620
M782 M903 M904 M910 P816 R032 V0 V621 V901 V917
V922

Specific Compounds

01851M

Chemical Indexing M2 *02*

Fragmentation Code

H402 H482 H721 J0 J011 J171 J271 M220 M222 M223
M224 M225 M231 M262 M281 M313 M320 M321 M332 M343
M383 M391 M416 M431 M620 M782 M903 M904 P816

Specific Compounds

90101M 90108M 90109M

Chemical Indexing M6 *03*

Fragmentation Code

M903 P816 R112 R200

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0121U; 0122U ; 1061U ; 1147U ; 1226U ; 1356U ; 1851U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1991-025026

WEST

Generate Collection

Print

L12: Entry 22 of 36

File: PGPB

Mar 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020028799
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020028799 A1

TITLE: Treatment of male sexual dysfunction

PUBLICATION-DATE: March 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Naylor, Alasdair Mark	Sandwich		GB	
Graaf, Pieter Hadewijn Van Der	Sandwich		GB	
Wayman, Christopher peter	Sandwich		GB	

APPL-NO: 09/ 895367 [PALM]
DATE FILED: June 29, 2001

RELATED-US-APPL-DATA:

Application is a non-provisional-of-provisional application 60/219100, filed July 18, 2000,
Application is a non-provisional-of-provisional application 60/265358, filed January 31, 2001,

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	DOC-ID	APPL-DATE
GB	0016684.3	2000GB-0016684.3	July 6, 2000
GB	0030647.2	2000GB-0030647.2	December 15, 2000
GB	0106167.0	2001GB-0106167.0	March 13, 2001
GB	0108483.9	2001GB-0108483.9	April 4, 2001

INT-CL: [07] A61 K 31/5377, A61 K 31/496, A61 K 31/53, A61 K 31/519

US-CL-PUBLISHED: 514/210.21; 514/234.2, 514/246, 514/252.16, 514/258, 514/362

US-CL-CURRENT: 514/210.21; 514/234.2, 514/246, 514/252.16, 514/259.3, 514/362

ABSTRACT:

The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type 5 (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.

[0001] This application claims priority from provisional application U.S. serial No. 60/219,100 filed Jul. 19, 2000 and from provisional application U.S. serial No. 60/265,358 filed Jan. 31, 2001 the benefit of which is hereby claimed under 37 C.F.R..sctn.1 .78(a)(3).

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
	<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR</i>		
<u>L1</u>	(mucosal or mucosa or buccal or oral) and (cmc or hpmc) and film and (disolve or dissolve or dissolution or disintigration)	794	<u>L1</u>
<u>L2</u>	active and (mucosal or mucosa or buccal or oral) and (cmc or hpmc) and film and (disolve or dissolve or dissolution or disintigration)	751	<u>L2</u>
<u>L3</u>	dysfunction and active and (mucosal or mucosa or buccal or oral) and (cmc or hpmc) and film and (disolve or dissolve or dissolution or disintigration)	104	<u>L3</u>
<u>L4</u>	(sexual or impotence or impotency) and dysfunction and active and (mucosal or mucosa or buccal or oral) and (cmc or hpmc) and film and (disolve or dissolve or dissolution or disintigration)	43	<u>L4</u>
<u>L5</u>	unit and dosage and film	18851	<u>L5</u>
<u>L6</u>	L3 and L5	100	<u>L6</u>
<u>L7</u>	"buccal film"	1	<u>L7</u>
<u>L8</u>	campfiled and davidovich and infeld	0	<u>L8</u>
<u>L9</u>	campfield and davidovich and infeld	6	<u>L9</u>
<u>L10</u>	L1 and (campfield or davidovich or infeld or unowsky)	14	<u>L10</u>
<u>L11</u>	L5 and buccal	2137	<u>L11</u>
<u>L12</u>	L3 and buccal	36	<u>L12</u>

END OF SEARCH HISTORY